Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 2
Submit an article Journal homepage
43
Views
5
CrossRef citations to date
0
Altmetric
Review

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia

Rodrigo Alonso Fundación Jiménez Díaz, Lipid Clinic, Internal Medicine Department, Madrid 28040, Spain. [email protected]
,
Nelva Mata Hospital Universitario Puerto Real, Public Health Department, Cádiz, Spain
&
Pedro Mata Fundación Jiménez Díaz, Lipid Clinic, Internal Medicine Department, Madrid 28040, Spain. [email protected]
Pages 171-181 | Published online: 22 Apr 2005

Bibliography

  • GOLDSTEIN JL, HOBBS HH, BROWN MS: Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The metabolic and molecular basis of inherited diseases. Nueva York: McGraw-Hill (2001) 120:2863–2913
  • HEATH K, GAHAN M, WHITTALL R, HUMPHRIES S: Low-density lipoprotein receptor gene (LDL-R) world-wide website in familial hypercholesterolemia: update, new features and mutations analysis. Atherosclerosis (2001) 154:243–246
  • INTERNATIONAL PANEL ON MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis (2004) 173:55–68.
  • ••First international guidelines for thediagnosis and management of FH. Cardiovascular risk stratification is proposed. Review of the most recent information about treatment.
  • SCIENTIFIC STEERING COMMITTEE on behalf of the Simon Broome register: Risk of fatal coronary heart disease in familial hypercholesterolemia. BE Med. J. (1991) 303:893–896.
  • MABUCHI H, KOIZUMI J, SHIMIZU M, TAKEDA R: Development of coronary heart disease in familial hypercholesterolemia. Circulation (1989) 79:225–232.
  • ••Interesting study that demonstrated thehigh incidence of premature miocardial nifartcion and coronary deaths in FH patients. Also, angiography studies demonstrated that atherosclerosis is detectable since 17 and 25 yrs old in males and females.
  • MATA P, ALONSO R, CASTILLO S, POCOVI M: MedPed and the Spanish familial hypercholesterolemia foundation. Atherosclerosis (2002) (supp1.2):9–11
  • ALONSO R, CASTILLO S, CIVEIRA F et al: Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases. Med. Clin. (Barc) (2002) 118:487–492.
  • TYBJAERG-HANSEN A, HUMPHRIES SE: Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature cardiovascular disease. Atherosclerosis (1992) 96:91–107.
  • KOTZE MJ, PEETERS AV, LANGENHOVEN E et al: Phenotypic expression and frequency of familial defective apolipoprotein B 100 in Belgian hypercholesterolemics. Atherosclerosis (1994) 111:217–225
  • VARRET M, RABES JP, SAINT-JORE B et al: A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.Am. J. Hum. Genet. (1999) 64:1378–1387
  • BERGE KE, TIAN H, GRAF GA et al: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290:1771–1775
  • ZULIANI G, ARCA M, SIGNORE A et al: Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1999) 19:802–809.
  • PULLINGER C, ENG C, SALEN G et al: Human cholesterol 7a-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. Clin. Invest. (2002) 110:109–117.
  • CELERMAJER DS, SORENSEN KW, GOOCH VM et al: Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.Lancet (1992) 340:1111–1115.
  • SANPIETRO T, TUONI M, FERDEGHINI M et al: Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation (1997) 96:1381–1385
  • ALONSO R, MATA P, DE ANDRES R et al.: Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis (2001) 157:423–429.
  • ••Long term treatment of FH patients withsimvastatin produced an improvement on endothelial function measured as flow-mediated dilatation in brachial aretry, not related to the effect on LDL-C. Also, a reduction in some soluble adhesion molecules was observed, indicating a normalization of the endothelium.
  • TAMAI 0, MATSUOKA H, ITABE H et al: Single LDL-apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation (1997) 95:76–82.
  • KANE JP, MALLOY MJ, PORTS TA et al: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA (1990) 264:3007–3012
  • ••One of the first angiographic trials in FHpatients that conclude that an agressive reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in these patients.
  • THOMPSON GR, MAHER VMG, MATTHEWS S et al: Familial Hypercholesteorlemia regression study: A randomised trial of low density lipoprotein apheresis. Lancet (1995) 345:811–816
  • EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). "AMA (2001) 285:2486–2495.
  • STEIN E, STENDER S, MATA P et al: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. (2004) 148:447–455.
  • ••Randomised, double-blind trial thatdemonstrated that the addition of ezetimibe to the starting dose of 10 mg/ day of atorvastatin followed by response-based atorvastatin dose titration (up to 40 mg/day) is more effective in reducing LDL-C levels in patients at high risk for CHD than continued doubling of atorvastatin as high as 80 mg/day alone. More patients achieved the goal in LDL-C (below 100 mg/d0.
  • RAUCH U, OSENDE JI, CHESEBRO JH et al.: Statins and Cardiovascular diseases: multiple effects of lipid-lowering therapy by statins. Atherosclerosis (2000) 153:181–189
  • NO AUTHORS: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • SHEPHERD J, COBBE S, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N. Engl. J. Med. (1995) 333:1301–1307
  • SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events in patients with average cholesterol levels (CARE). N Engl. J. Med. (1996) 335:1001–1009.
  • DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS/ TexCAPS). JAMA (1998) 279:1615–1622.
  • THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cohlesterol levels. N Engl. J. Med. (1998) 339:1349–1357
  • HEART PROTECTIVE STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7–22
  • SCIENTIFIC STEERING COMMITTEE on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis (1999) 142:105–112.
  • KNOPS RE, KROON AA, MOL MJ et al.: Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolemia. Neth. Med. (1995) 46:171–178.
  • OSE L, KASTELEIN J, SCOTT R et al: Efficacy and six-month safety of simvastatin 80 mg/day: Results from the worldwide simvastatin expanded dose program (WSEDP). Num. Metab. Cardiovasc. Dis. (1998) 8:135–143
  • DE SAUVAGE NOLTING P, BURIMA R, HUTTEN B et al.: Two-year effciacy and safety of simvastatin 80 mg in familial hypercholesterolemia (The examination of probands and relatives in statin studies with familial hypercholesterolemia lExPRESS FH1). Am. J. Cardiol (2002) 90:181–184
  • ••Open label multicenter study, usingsimvastatin 80 mg/day during 2 years in 508 patients with clinical and/or genetic diagnosis of FH. A reduction of 48% in LDL-C and an increase of 13% in HDL-C was observed. Significant adverse event rate was low.
  • MATA P, ALONSO R, BADIMON JJ: Benefits and risks of simvastatin in patients with familial hypercholesterolemia. Drug Sal: (2003) 26:769–786.
  • TODD PA, GOA KL: Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs (1990) 40:583–607.
  • PLOSKER G, MCTAVISH D: Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs (1995) 50:334–363
  • MAURO VF: Clinical pharmacokinets and practical applications of simvastatin. Pharmacokinet. (1993) 24:195–202.
  • CHENG H, ROGERS JD, SWEANY AE et al.: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzime A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. (1992) 9:1629–1633
  • GRUERP, VEGA JM, MERCURI Metal.: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. Cardiol (1998) 84:811–815.
  • PEDERSEN TR, WILHELMSEN L, FAERGEMAN 0 et al: Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am. Cardiol (2000) 86:257–262.
  • STRANDBERG PE, PYORALA K, COOK TJ et al: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 364:771–777.
  • RAAL FJ, PILCHER GJ, ILLINGWORTH DR et al: Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis (1997) 135:249–256.
  • RAAL FJ, PILCHER GJ, VELLER M et al: Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventig the progression of atherosclerosis in homozygous familial hypercholesterolemia - a direct measurement with ultrasound imaging. Am. J. Cardiol (1999) 84:1344–1346.
  • MOL MJ, ERKELENS DW, GEVERS LEUVEN JA et al: Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet (1986) 8513:936–939.
  • MOL MJ, ERKELENS DW, GEVERS LEUVEN JA et al: Simvatatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis (1988) 69:131–137.
  • HAGEMENAS FC, PAPPU AS, ILLINGWORTH DR.: The effect of simvastatin on plasma liporptoeins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur. Clin. Invest. (1990) 20:150–157.
  • DE SAUVAGE NOLTING P, BURIMA R, HUTTEN B et al: Baseline lipid values partly determine the response to high dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in statin studies with familial hypercholesterolemia lExPRESS FH1 Atherosclerosis (2002) 164:347–354.
  • ILLINGWORTH DR, BACON S, PAPPU A et al: Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis (1992) 96:53–64.
  • WIERZBICKI AS, LUMB PJ, SEMRA Y, CHIK G, CHRIST ER, CROOK MA: Atorvastatin compared with simvastatin-based therapies in the management of severe familial hypercholesterolemias. Q. I Med. (1999) 92:387–394.
  • WIERZBICKI AS, LUMB PJ, SEMRA YK, CROOK MA: High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolemia.Med. (1998)91:291–294.
  • WIERZBICKI AS, LUMB PJ, CHIK G, CROOK MA: Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolemia. Int. Clin. Pract. (1999) 53:609–611
  • STEIN EA, ILLINGWORTH DR, KWITEROVICH PO et al: Efficacy and safety of lovastatin in adolescents males with heterozygous familial hypercholesterolemia: a randomised controlled trial. JAMA (1999) 281:137–144.
  • WIEGMAN A, HUTTEN BA, DE GROOT E et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 292:331–337.
  • ••First study that demonstrated thatlong-term statin therapy reduces carotid atherosclerosis (measured as carotid IMT) In children with FH. No adverse effects on growth, hormone levels and sexual maturation were observed.
  • CROWFORD ML: From the Food and Drug Administration. JAMA (2002) 287:1640.
  • STEIN EA: Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis (1989) 9\(supp1.1):I1454151.
  • DUCOBU J, BRASSEUR D, CHAUDRON S et al: Simvastatin use in children (Letter). Lancet (1992) 339:1488.
  • STEFANUTTI C, LUCANI G, VIVENZIO A, DI GIACOMO S: Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drug Expd. Clin. Res. (1999) 25:23–28.
  • DIRISAMER A, HACHEMIAN N, BUCEK Ra, WOLF F, REITER M, WIDHALM K: The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur. Pediatr. (2003) 162:421–425.
  • DE JONGH S, OSE L, SZAMOSI T et al: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a ranomized, double-blind, placebo-controlled trial with simvastatin. Circulation (2002) 106:2231–2237.
  • ••A randomised, double-blind trial usingsimvastatin from 10 to 40 mg/day versus placebo in 173 children with FH during 1 year. Simvastatin significantly reduced LDL-C (41%), and high dose (40 mg/day) was well tolerated.
  • DE JONGH S, LILIEN MR, OPT ROODT J, STROES ES, BAKKER HD, KASTELEIN JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Am. Cardiol. (2002) 40:2117–2121.
  • SIJBRANDS E, LOMBARDI MP, WESTENDORP R et al: Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis (1998) 139:247–253
  • HEATH K, GUDNASON V, HUMPHRIES SE et al.: The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis (1999) 143:41–54.
  • CHAVES FJ, REAL JT, GARCIA-GARCIA AB et al: Genetic diagnosis of familial hypercholesterolemia in a South European outbread population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and High-density lipoprotein cholestero. Endocrinol. Metab. (2001) 86:4926–4932.
  • VOHL MC, SZOTS F, LELIEVRE M et al: Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 160:361–368.
  • COUTURE P, BRUN LD, SZOTS et al: Association of specific LDL receptor-gene mutations with differential plasma liporprotein response to simvastatin in young French-Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1007–1012.
  • CASTILLO S, REYES G, TEJEDOR D et al: A double mutant (N543H-F2393de19) allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. Hum. Mutat. (2002) (online)
  • BRENSIKE JF, LEVY RI, KELSEY SF et al: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II coronary intervention study. Circulation (1984) 69:313–324.
  • KROON AA, AENGEVAEREN W, VAN DER WERF T et al.: LDL-Apheresis atherosclerosis regression study (LAARS). Effect of agressive versus conventional lowering treatment on coronary atherosclerosis. Circulation (1996) 93:1826–1835.
  • ••A 2 year study which showed thatsimvastatin alone or in combination with LDL-apheresis, arrested the angiographic progression of coronary artery disease. A more aggressive treatment induced functional improvement that can precede the anatomical changes.
  • KROON A, VAN ASTEN W, STALENHOEF A: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercohlesterolemic patients with coronary artery disease. Ann. Intern. Med. (1996) 125:945–954.
  • SMILDE TJ, WISSEN S, WOLLERSHEIM H et al: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet (2001) 357:577–581.
  • ••Interesting study that confirms that anaggressive statin therapy (reduction in LDL-C levels over 45%) in FH patients is accompanied by regression of carotid IMT. A conventional therapy did not show anatomical benefit.
  • DE SAUVAGE NOLTING P, DE GROOT E, ZWINDERMAN A et al: Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia. Arch. Intern. Med. (2003) 163:1837–1841.
  • CORTI R, BADIMON J: Value or desirable of hemorheological-hemostatic parameter changes asendpoints in blood lipid-regulatin trials. Curr. Opin. Lipidol. (2001) 12:629–637
  • TAKEMOTO M, LIAO J: Pleiotropic effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1712–1719.
  • SIMONS LA, SULLIVAN D, SIOMONS J et al: Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endotelial function in patients with severe primary hipercolesterolemia. Atherosclerosis (1998) 137:197–203.
  • YOKOYAMA I, YONEKURA K, INOUE Y et al: Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J. Nucl. Cardiol (2001) 8:445–451.
  • GIRONA J, LA VILLE AE, SOLAR et al.:Simvastatin decreases aldehyde production derived from liporptoein oxidation. Am. J. Cardiol (1999) 83:846–851
  • TOMAS M, SENTI M, GARCIA-FARIA F et al.: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2113–2119
  • DEMUTH K, MYARA I, CHAPPEY B et al.: A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vasc. Biol. (1996) 16:773–783.
  • BENITEZ S, ORDONEZ-LLANOS J, FRANCO M et al.: Effect of simvastatin in familial hipercolesterolemia on the affinity of electronegative low-density lipoprotein subfraction to the low-density lipoprotein receptor. Am. Cardiol (2004) 93:414–420.
  • SANCHEZ-QUESADA J, OTAL-ENTRAIGAS C, FRANCO M et al.: Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol (1999) 84:665–659
  • FERRO D, BASILI S, ALESSANDRI C et al.: Simvastatin reduces monocyte-tissue-factor expression in Type Ha hypercholesterolaemia. Lancet (1997) 350:12–22.
  • REZAIE-MAJD A, MACA T, BUCEK R et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocyte from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1194–1199
  • RAUCH U, OSENDE JI, CHESEBRO JH et al: Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis (2000) 153:181–189.
  • CORTI R, FUSTER V, FAYAD ZA et al: Lipid-lowering by simvastatin induces regression of human atherosclerotic lesions: 2 year follow-up by high-resolution noninvasive MRI. Circulation (2002) 106:2884–2887.
  • ••The study demonstrated that maintainedsimvastatin therapy (with a sustained 38% reduction in LDL-C levels) was associated with significant regression of established atherosclerotic lesions in humans measured by magnetic resonance imaging.
  • BOCCUZZI SJ, KEEGAN ME, HIRSCH LJ et al: Long-term experience with simvastatin. Drug Invest. (1993) 5:135–140.
  • STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl. I Med. (2002) 346:539–540.
  • LUNEN P, CELIS H, FAGARD R et al:Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J. Hypertens. (1994) 12:59–64.
  • LAAKSONEN R, JOKELAINEN K, SAHI T et al: Decrease in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Parmacol Ther. (1995) 57:62–66.
  • EVANS M, REES A: The myotocicity ofstatins. Curt: Opin. Lipidol (2002) 13:415–420.
  • UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Sal: (2000) 22:441–457.
  • EVANS M, REES A: Effects of HMG-CoAreductase inhibitors on skeletal muscle. Are all statins the same?. Drug Sal (2002) 25:649–663
  • PASTERNAK R, SMITH S, BAIREY-MERZ CN et al: ACC/AHA/ NHLBI Clinical advisory on the use and safety of statins. Circulation (2002) 106:1024–1028.
  • GOLDMAN L, GOLDMAN PA, WILLIAMS LW et al: Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J. Cardiol (1993) 72:75D–79D.
  • JOHANNESSON M, JONSONN B, KJEKSHUS J et al: Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl. J. Med. (1997) 336:332–336
  • WORLD HEALTH ORGANISATION, Human Genetics Program, Division of Non-communicable diseases: Familial Hypercholesterolemia, report of a WHO consultation. WHO/HGN/FH/CONS/ 98.7.Paris, October 1997.
  • DURRINGTON P: The human and economic costs of undertreatment with statins. Int. I Clin. Pract. (2002) 56:357–368.

Websites

  • http://www.ucl.ac.uldfh University College London web site, The low density lipoprotein receptor (LDLR) gene in familial hypercholesterolemia

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.